Author:
Matsuda Ryota,Miyasaka Yoshihiro,Ohishi Yoshihiro,Yamamoto Takeo,Saeki Kiyoshi,Mochidome Naoki,Abe Atsushi,Ozono Keigo,Shindo Koji,Ohtsuka Takao,Kikutake Chie,Nakamura Masafumi,Oda Yoshinao
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference28 articles.
1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014
3. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01);Uesaka;Lancet,2016
4. Pancreatic cancer in the remnant pancreas following primary pancreatic resection;Hashimoto;Surg Today,2014
5. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer;Smeenk;Dig Surg,2005